Abstract: Provided is radiolabeled ammonium salts and uses thereof as myocardial perfusion agents in molecular imaging.

Abstract: A retrieval apparatus for entrapping and retaining an object located in a body for its extraction therefrom is described. The retrieval apparatus includes a snare and a snare control assembly. The snare has a proximal section and a distal section, and comprises a plurality of filaments extending from a proximal end of the proximal section towards the distal section, and then returning to the proximal end to form a plurality of loops. In the deployed state, the loops are interlaced to each other within the proximal section and are free and not interleaved within the distal section. Segments of the filaments of the distal section are bent with respect to segments of the filaments of the proximal section such that the retrieval snare in the contracted, state forms a hollow cavity extending from die distal section towards the proximal section.

Abstract: A cutting balloon assembly and a method for fabrication of the assembly is described. The cutting balloon assembly comprises a delivery catheter, an expandable balloon mounted on the catheter distal end, and a scoring mesh disposed around the expandable balloon. The scoring mesh comprises interlacing filaments that extend from a mesh proximal end towards a mesh distal end, form distal filament loops at said mesh distal end, and then return to the mesh proximal end. At least a part of the interlacing filaments forms one or more permanent links with neighboring filaments between the mesh proximal end and the mesh distal end.

Abstract: A method for fabrication of a cutting balloon assembly is described. The method includes providing a predetermined number of filaments having predetermined properties, diameter and length and fabricating a scoring mesh on a weaving jig having a plurality of pins disposed circumferentially about the jig's surface. The fabrication of the scoring mesh includes placing the filaments between the pins and interlacing the filaments to form a scoring mesh by interweaving and intertwining at least a part of filament to form one or more permanent links with neighboring filaments. The fabrication of the scoring mesh also includes forming distal and proximal filament loops that protrude from the mesh distal and proximal ends, respectfully. The scoring mesh is mounted on an expandable balloon mounted on a distal end of a delivery catheter.

Abstract: A retrieval apparatus for entrapping and retaining an object located in a body for its extraction therefrom is described. The retrieval apparatus includes a snare and a snare control assembly. The snare has a proximal section and a distal section, and comprises a plurality of filaments extending from a proximal end of the proximal section towards the distal section, and then returning to the proximal end to form a plurality of loops. In the deployed state, the loops are interlaced to each other within the proximal section and are free and not interleaved within the distal section. Segments of the filaments of the distal section are bent with respect to segments of the filaments of the proximal section such that the retrieval snare in the contracted, state forms a hollow cavity extending from die distal section towards the proximal section.

Abstract: A retrieval apparatus for entrapping and retaining an object located in a body for its extraction therefrom is described. The retrieval apparatus includes a snare and a snare control assembly. The snare has a proximal section and a distal section, and comprises a plurality of filaments extending from a proximal end of the proximal section towards the distal section, and then returning to the proximal end to form a plurality of loops. In the deployed state, the loops are interlaced to each other within the proximal section and are free and not interleaved within the distal section. Segments of the filaments of the distal section are bent with respect to segments of the filaments of the proximal section such that the retrieval snare in the contracted state forms a hollow cavity extending from the distal section towards the proximal section.

Abstract: A method for fabrication of a cutting balloon assembly is described. The method includes providing a predetermined number of filaments having predetermined properties, diameter and length and fabricating a scoring mesh on a weaving jig having a plurality of pins disposed circumferentially about the jig's surface. The fabrication of the scoring mesh includes placing the filaments between the pins and interlacing the filaments to form a scoring mesh by interweaving and intertwining at least a part of filament to form one or more permanent links with neighboring filaments. The fabrication of the scoring mesh also includes forming distal and proximal filament loops that protrude from the mesh distal and proximal ends, respectfully. The scoring mesh is mounted on an expandable balloon mounted on a distal end of a delivery catheter.

Abstract: A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.

Abstract: Provided is radiolabeled ammonium salts and uses thereof as myocardial perfusion agents in molecular imaging.

Abstract: A cutting balloon assembly and a method for fabrication of the assembly is described. The cutting balloon assembly comprises a delivery catheter, an expandable balloon mounted on the catheter distal end, and a scoring mesh disposed around the expandable balloon. The scoring mesh comprises interlacing filaments that extend from a mesh proximal end towards a mesh distal end, form distal filament loops at said mesh distal end, and then return to the mesh proximal end. At least a part of the interlacing filaments forms one or more permanent links with neighboring filaments between the mesh proximal end and the mesh distal end.

Abstract: A novel method of treating endometriosis is disclosed. The method comprises administering to a female subject in need thereof a therapeutically effective amount of particles comprising an agent capable of inhibiting phagocytic cells of the female subject.

Abstract: A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.

Abstract: The present invention relates to methods and compositions designed for the prevention, reduction, treatment or management of ischemia-reperfusion injury. The methods of the invention comprise the administration of an effective amount of a therapeutic formulation containing one or more active compounds in a formulation which specifically decreases or inhibits the activity of and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and/or monocytes. In preferred embodiments, the active compound is a bisphosphonate. The invention also provides pharmaceutical compositions of therapeutic formulations for administration to subjects currently suffering from, having recently suffered, or at risk of suffering from an ischemia-reperfusion injury.

Abstract: A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.

Abstract: A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.

Abstract: Bisphosphonate (BP), pyrophosphate (PP) a complex of BP or PP, a polymer of BP or PP or pharmaceutically acceptable salt or ester thereof, are used for the prevention or treatment of vascular restenosis.

Abstract: A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.

Abstract: A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.